How Long Does Keytruda's FDA Approval Process Take?
What was the timeline of Keytruda's FDA approval?
Pembrolizumab, commonly known as Keytruda, is an immunotherapy drug developed by Merck & Co. Keytruda received FDA approval on September 4, 2014, for treating certain types of melanoma. [1] The journey from clinical trials to FDA approval for Keytruda took around 6-7 years.
What were the earlier stages of development?
Research on the PD-1 receptor, a target of Keytruda, dates back to the early 2000s. Studies on the role of immune checkpoints in cancer began in 2004, and the FDA granted orphan drug status to pembrolizumab for melanoma in 2010. Clinical trials for Keytruda started in 2011.
How did Keytruda's clinical trials shape its FDA approval process?
Pembrolizumab's clinical trials demonstrated its effectiveness in treating advanced melanoma and other types of cancer. Keytruda's approval was based on the results of two trials, KEYNOTE-006 and KEYNOTE-001. The phase 3 KEYNOTE-006 trial showed a significant improvement in overall survival for patients taking pembrolizumab compared to a combination of ipilimumab and dacarbazine. [2]
Why did Keytruda receive accelerated FDA approval?
Keytruda was granted accelerated approval by the FDA for the treatment of patients with unresectable or metastatic melanoma due to its significant clinical benefit in trials. However, its approval was contingent upon the verification of clinical benefit in controlled trials.
Key Takeaways
Keytruda's journey to FDA approval involved over 6 years of clinical trials and development. It was granted accelerated approval in 2014 for certain types of melanoma.
References
[1] FDA Approves Merck’s Keytruda for Advanced Melanoma. (September 4, 2014). Available at https://www.drugpatentwatch.com/patent-news/fda-approves-keytruda-for-advanced-melanoma/
DrugPatentWatch.com [online]. FDA Approves Merck's Keytruda for Advanced Melanoma. 2022. https://www.drugpatentwatch.com/patent-news/fda-approves-keytruda-for-advanced-melanoma/